OptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call Transcript

OptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call Transcript March 28, 2024

OptimizeRx Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good morning, everyone and thank you for joining OptimizeRx’s Fourth Quarter Fiscal 2023 Conference Call. With us today is the Chief Executive Officer of OptimizeRx, William Febbo. He is joined by Chief Financial Officer, Ed Stelmakh; President Steve Silvestro; General Counsel Marion Odence-Ford; and Senior Vice President of Corporate Finance, Andrew D’Silva. At the conclusion of today’s earnings call, I will provide some important cautions regarding the forward-looking statements made by management during today’s call. I would like to remind everyone that today’s call is being recorded and will be made available for replay via webcast. And a transcript and a link to the audio recording of this conference call, will be provided on the Investors section of the company’s website. Now I would like to turn the call over to OptimizeRx CEO, William Febbo. Sir, please go ahead.

William Febbo: Good morning. And thank you for joining our conference call to discuss fourth quarter 2023 preliminary unaudited financials. As already communicated our audit is taking longer than previous years due to the October 2023 acquisition of Healthy Offers Inc. which does business under the name of Medicx Health. The November 2023 solutions portfolio streamlining around core business lines in the validation and testing of certain third party vendors, internal processes that are part of our previously disclosed material weakness remediation plan. The audit is in the final stages, and we are confident that we will be in a position to file our 10-K and audited financials no later than April 15. I’m pleased to note that Q4 represented a strong end to 2023 and has favorably positioned us to start 2024.

The quarter’s financial results came in better than our initial expectations and topped analyst estimates, with Q4 revenue growing 44% year-over-year to $28.4 million. The improvement was driven by strong organic growth in messaging, led by our Dynamic Audience Activation platform or DAAP death for short, as well as from approximately two months of contribution from our acquisition of Medicx Health. Notably, our legacy core HCP business grew by over 30% when compared to the fourth quarter of 2022. We are excited about the many business highlights from the fourth quarter. We continue to validate our thesis on DAAP, as we increase the number of deals in 2023 to ’24 deals, providing us with a significant revenue launch pad this year. Progress coming in ahead of what we had anticipated is very favorable as by their nature, these DAAP deals are larger, stickier and more strategically targeted, making us more relevant partner with our client base.

We also acquired Medicx Health, resulting in the combination of a leading direct to consumer audience activation and messaging execution business. With our HCP focused Omni channel digital point of care marketing business. This acquisition unlocks a significant adjacent market with an extremely large whitespace and cross sell opportunity. The integration of Medicx Health is tracking ahead of schedule, and the majority of integration activities have been completed. Furthermore, we have optimized our operation by trimming our legacy OptimizeRx costs by over 10% and simultaneously realigning our focus on core business lines and moving away from non-core business. As noted in our March 11 2024 press release, we are reiterating our guidance for 2024 but revising our original 2024 revenue target.

This revision is due to the change in the revenue accounting treatment for certain revenue streams, or messaging executed through Medicx Health channel partners that were historically recognized on a gross basis, but now will be recognized on a net basis. As a consequence of this gross to net accounting treatment, we adjusted our revenue target anticipate revenue to reach at least $100 million for 2024. Importantly, this adjustment maintains our bottom line and in fact enhances our margin profile. Therefore, our adjusted EBITDA guidance remains unchanged, standing at least $11 million for 2024. We believe the macroeconomic and competitive challenges we identified in 2022 and 2023 are returning to normal. In particular, we’re witnessing encouraging momentum as our clients that had initiated pilot programs with newly established entrants in our field over the past two years, are concluding the assessments of these programs and anticipated are finding that these proceeds competitive solutions lack scalability and the ability to adequately report information back to customers, ultimately driving spending back towards our offerings.

Before proceeding, I’d like to express my sincere gratitude to the OptimizeRx team for their unwavering dedication and relentless pursuit of our mission. Over the past two years, our collective efforts have led to the development of one of the most scalable solutions in the industry, tailored specifically for pharmaceutical marketers. We’ve recently expanded this initiative to include a highly impactful DTC component. This journey hasn’t been without its challenges. Navigating through the dynamic landscape of the industry shifts and embracing early digital advancements has been no small task yet, OptimizeRx’s achievements, and as a testament to our resilience and foresight. Fundamentally reshaping the dynamics of engagement between pharma patients and prescribers.

As previously mentioned, in September of last year, we introduced a significant enhancement to our Omni channel healthcare engagement platform, known as DAAP. This pioneering AI driven capability seamlessly integrates point of care and traditional digital media, offering holistic solution for pharmaceutical marketing. The unveiling marked the culmination of years dedicated to the understanding of how AI can augment OptimizeRx’s customer use cases, resulting in a transformative journey, or HCP engagement platform. Building upon our existing technology, we have extended the AI driven platform reach compass, social media, web display channels, and CRM alerts, which fosters greater efficiency to collaboration with our customer sales forces. Since then, we’ve expanded these capabilities to now also encompass the DTC channels utilized by Medicx Health, that includes streaming and connected TV, as well as various digital channels such as display audio, online video, and mobile among others.

We are encouraged by this timeline enhancements, as we’ve already witnessed early initial cross selling success with DAAP, in the short time since we’ve consummated the acquisition. We will update everyone regarding our DAAP cross selling efforts in our Q1 earnings call in early May. DAAP advances our land and expand strategy, enabling clients to gain maximum market penetration through the scaling of outreach in real time, across the company’s network of over 2 million HCPs and 240 million U.S. adults across multiple major digital media channels and at point-of-care via EHRs e-Prescribing and Telehealth platforms. With this OptimizeRx is evolved into one of the most comprehensive digital healthcare marketing platforms in the nation. This evolution firmly aligns with current pharma trends, as the industry is moving to a greater portion of their commercial spend towards Omni channel digital solutions.

While looking for these solutions to deliver more impactful results, by not only identifying patients known to HCPs, but also pinpointing new patients for their therapies. We continue to believe smarter solutions such as our DAAP offering, will captures the lion’s share of the pharma spend particularly with legacy commercial dollars that are reallocated to digital. We believe early proof of this trend is clearly highlighted by the 4x year-over-year increase in DAAP deal seen in 2023. DAAP represents a transformative lead for us, transitioning us from being a mere tactical player within the pharmaceutical industry to a formidable strategic partner. This shift affords us the invaluable advantage of garnering top-down support from decision makers, while also securing revenue streams with greater durability, enhanced margin and amplified growth prospects.

These pivotal developments are reinforcing my level of excitement regarding our strategic positioning. I anticipate that the collective impact of our initiatives outlined today could yield substantial dividends over the next three to five years, catapulting our revenue to multiples of its current standing. As we diligently pursue our land and expand strategy, we continue to reap the rewards of delivering superior return on investment, maintaining our impressive ROI of over 10:1 for HCP messaging. This achievement holds particular significance with the pharmaceutical landscape, where achieving ROI is of two to three times spent and has traditionally been the benchmark. We believe we turned a significant corner in recent months and have incredible momentum going into 2024.

And with that, I’d like to turn the call over to our CFO, Ed Stelmakh, who will walk us through our financial details. Ed?

Edward Stelmakh : Thanks Will, and good morning everyone. As noted previously, a transcript and a link to an audio recording of this conference call will be provided on the Investor section of the company’s website. Fourth quarter revenue came in at $28.4 million, an increase of 44% from the $19.7 million we recognize during the same period in 2022. This included revenues from our legacy core and non-core business lines as well as from approximately two months of Medicx Health related revenue streams. Going forward, we will be reporting both OptimizeRx and Medicx Health as one consolidated business. Meanwhile, our previous non-core business lines that we have called access and patient engagement will no longer be revenue streams for the company.

And we have eliminated associated costs to these business lines. On a pro forma basis when stripping out these non-core business lines from our 2023 results, and accounting for the full year benefit of Medicx Health financial results in our 2023 actuals, our revenue for calendar year 2023 would have been approximately $91.8 million, which we are utilizing as our comparison point to jog progress going forward. Meanwhile, our net loss came in at $7.2 million for the fourth quarter of 2023, compared to a loss of $0.3 million during the fourth quarter of 2022. Our adjusted EBITDA came in at $5.8 million for the fourth quarter of 2023, compared to $3.9 million during the fourth quarter of 2022. GAAP to non-GAAP reconciliation table has been included in the Investor Relations section of our website @investors.optimizerx.com, in the events and presentations folder.

We ended the year with cash and short term investments totaling $13.9 million as of December 31 2023, as compared to $74.1 million on December 31 2022. The majority of the year-over-year decline was due to our acquisition of Medicx Health and share repurchase program, which we bought back 526,999 shares of common stock for $7.5 million during 2023. Our current debt balance currently stands at $38.3 million, recall to help fund the $83.9 million cash portion of the Medicx Health transaction. The company took on $40 million in debt financing. And we paid off $1.7 million of principal during the fourth quarter. We continue to believe we’re well funded to execute against our operational goals. And with that, I would like to turn the ball back over to Will.

Will?

William Febbo: Thanks, Ed. Operator, now let’s move to Q&A.

See also 25 Best Asana Alternatives & Competitors for Project Management in 2024 and 25 Things Every Dividend Investor Should Know.

Q&A Session

Operator: [Operator Instructions] Our first question is from Sean Dodge, with RBC Capital Markets. Please proceed with your question.

Sean Dodge: Thanks. Good morning, and congratulations on the strong finish to the year. You signed, Will you said ’24 DAAP yields in ’23 that was up 4x four times versus the previous year. So lots of momentum there. I just anything you can share on how demand or activity around those have carried into this year, you had mentioned some macro headwinds before those continues to dissipate?

William Febbo: Hey, Sean, yes, thanks. So yeah, on macro, for sure, we’re seeing sort of a return to what we saw in ’21 in terms of our clients making decisions, flow, seasonality, all that good stuff, FDA approvals all, you know, tracking towards previous dip. And yeah, the will obviously talk to Q1 in May. But, you know that it’s really resonating with the clients, I think we talked a lot about it through the Q3 report that clients are really the adoption of digital has also forced the adoption of accuracy reporting, data driven outreach. Less is more if it’s effective. And we’re in the right place at the right time there with this innovative approach. So, yeah continued adoption. And I’ll let Steve, just to say a couple of top level words on the sales training and such.

But very, very positive momentum, and really encouraged by the team’s ability to deliver in a way that the clients respond to in a way that’s efficient around digital. Steve do you want to just chime in a little bit?

Steve Silvestro: Yes, happy to Hey, Sean, good to hear you. I think one of the other things that’s been really encouraging is that the initial set of DAAP deals that we did previously, have renewed, and those same set of clients have expanded. So I think that’s also a positive confirmation on value prop and what we’re delivering to those clients, Sean. So, that land and expand strategy that we talked about previously, is really coming to fruition. And I think, as Will highlighted, the team’s ability to get a little bit more technical, and approach the client in a different way that the sales slightly different, right, it’s more of a much more of a strategic sale, in that you’re having a conversation around patient profiles and strategies a little bit more mature than we would have had in times past.

So really encouraged by that. And I think that makes it significantly more sticky. As well said, we’ll have more positive news to share during Q1, but really encouraged by what we’re seeing on the DAAP front.

Sean Dodge: Sure. And that’s a that’s a good segue into my follow up. Will you in your prepared remarks talked about Omni channel and kind of trends within big pharma. You’ve done the Medicx acquisition that had a lot of nice breaths for you, when we think about kind of Omni channel, do you have everything you need there? Now are there other areas or capabilities you think could make sense to bolt-on in the future?

William Febbo: So yes, I would say, look, we have no major CapEx, we’ve got the tech that can enable what we’re doing. We’re constantly looking at different types of channel partners. And I think, Sean, that’ll be an evolution pretty much every year. Because there’s just so much changing so fast, the way doctors and patients interact with their own medical records with their own doctors with their caregivers. And so luckily for us, we have a team and that was enhanced with a part of the Medicx team as well, that’s completely focused on channel. And Omni channel is really something that shifts with the needs, right? It’s not a stagnant thing. You don’t sort of get there and you’re done. It’s constantly evolving. But the good news is we’ve got a lot of reach today that is highly relevant that gives us growth, and we’ve got the team to be to keeping their eye on the ball, on what’s next in terms of enablement for communication with both HCPs and patients and consumers health.

Sean Dodge: Okay, that’s great color. Thanks, and congrats again.

Operator: Thank you. Our next question is from Stephanie Davis with Barclays. Please proceed with your question.

Stephanie Davis: Hi, guys, thanks for taking my questions. You’re talking about trimming costs further, but you’re talking mostly to a few different initiatives that wouldn’t normally require some headcount investments such as the DAAP wins and the Walmart partnership. Can you just walk us through how to think about that?

William Febbo: Yes, sure. Hey Stephanie, good to hear your voice. So no.

Stephanie Davis: Long time, no talk.

William Febbo: Yeah, no, right. Great conference, by the way. Thank you. So no, we’re not looking at additional costs, right. That was just all message last year. And we’re just reminding everyone that we completed it. The beauty of this model, Stephanie is we’re it’s a technology platform, right? We don’t — we’re not an agency, we don’t generate content. We help our clients get the content that they’ve already generated to the right people at the right time, whether that’s a doctor or a patient. So we are additional people this year, we’ll be commercially focused. And also, just as a public company, you know, having more than half this, we get over $100 million in revenue. And then as we’ve messaged before, on the reporting side, that’s a key piece to now that pharmaceutical companies have adopted point-of-care digitally as a channel.

All the standards go up, and transparency needs to go with it as well as measurement. So, now this is a very scalable model. We’ve shown it before in past years, even as a smaller company that investors go back and look and I think we’ll see that as we progress through the year.